APPROACH TO CLINICAL TRIALS AUTHORIZED IN BRAZIL BY THE NATIONAL HEALTH SURVEILLANCE AGENCY UNTIL JUNE 30, 2020
DOI:
https://doi.org/10.14450/2318-9312.v32.e2.a2020.pp107-108Keywords:
covid, anvisaAbstract
Com o surgimento da pandemia do coronavirus, houve uma dedicação intensa e relevante da comunidade científi ca à procura de novos medicamentos para tratamentos da Covid-19, devido à inexistência de vacinas e à necessidade emergencial de se evitar os óbitos crescentes em decorrência dos efeitos degenerativos no trato respiratório, provocados pela doença no organismo humano, principalmente nos pacientes do grupo de risco.
Downloads
Published
2020-07-07
How to Cite
Oliveira, A. G. de, & Silveira, D. (2020). APPROACH TO CLINICAL TRIALS AUTHORIZED IN BRAZIL BY THE NATIONAL HEALTH SURVEILLANCE AGENCY UNTIL JUNE 30, 2020. Infarma - Pharmaceutical Sciences, 32(2), 107–108. https://doi.org/10.14450/2318-9312.v32.e2.a2020.pp107-108
Issue
Section
Editorial
License
Authors who publish in this journal agree to the following terms:
- Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
- Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
- Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).
